

CURRENT REPORT

Date of Report (Date of earliest event reported): November 4, 2014

Delaware (State or other jurisdiction of incorporation)	001-34263 (Commission File Number)	65-0403311 (IRS Employer Identification No.)
----------------------------------------------------------------------	-------------------------------------------------	-----------------------------------------------------------

Registrant's telephone number, including area code: **(510)
240-6000**

Not Applicable
(Former name or former address, if changed since last report)

Edgar Filing: IMPAX LABORATORIES INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2014, Impax Laboratories, Inc. issued a press release announcing its results for the third quarter ended September 30, 2014. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith.

Exhibit No. Description

99.1 Press release issued November 4, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 4, 2014 **IMPAX LABORATORIES, INC.**

By: /s/ Bryan M. Reasons

Name: Bryan M. Reasons

Title: Senior VP, Chief Financial Officer

EXHIBIT INDEX

Exhibit No. Description

99.1 Press release issued November 4, 2014.